Monday, March 18, 2013
Diffusion Pharmaceuticals LLC, of Charlottesville, Va., said it completed enrollment in a Phase II trial of trans sodium crocetinate (TSC), an oxygen diffusion-enhancing compound.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.